Idera Pharmaceuticals Presents Positive Phase 1 Data for Intratumoral IMO-2125 in Combination with Ipilimumab Demonstrating an Overall Response Rate of 44% in Melanoma Patients Refractory to Anti-PD1 Therapy at ESMO 2017